Three-month testosterone updates: separating real changes from hype
Quick answer
The creator is approximately three months into masculinizing testosterone therapy and describes a symptom and change profile consistent with early androgenization: clitoral growth, menstrual suppression, early facial and body hair, and increased muscle mass. The timeline they describe aligns with published onset windows from Endocrine Society clinical practice guidelines for gender-affirming hormone therapy (Hembree et al., 2017, JCEM). No information is provided about formulation, dose, or whether labs are being monitored, which are standard components of medically supervised testosterone therapy.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @aidenkmoody45 actually say?
At three months on testosterone, this creator ran through a list of physical changes: clitoral growth starting immediately, cessation of periods by month two, body and facial hair coming in, noticeable muscle gain, a slightly wider foot, and a head circumference increase that made old hats fit differently. They also described feeling muscle growth before seeing it, and noted that breast tissue was responding to their weight training.
This is a first-person experiential update, not medical advice, and they frame it that way. But with 2,300 views and a hashtag set aimed at people researching FTM transition, the claims carry real-world weight. Some of what they described is well-supported by endocrinology literature. A few details are more complicated than a TikTok update can capture. And one or two things deserve a closer look.
Does the science back this up?
Mostly, yes. The timeline and sequence they described lines up reasonably well with published data on masculinizing hormone therapy. The Endocrine Society and WPATH guidelines, along with prospective cohort studies, give us a decent map of what testosterone does and when.
Clitoral growth (clinically called clitoromegaly or bottom growth) is among the earliest changes, often beginning within weeks of starting testosterone. Grimstad et al. (2021, Andrology) documented this as one of the first androgenic effects in FTM patients, consistent with the creator's report of noticing it "right away." Menstrual suppression typically occurs within two to six months; cessation by month two is on the faster end but entirely plausible (Nakamura et al., 2019, Obstetrics and Gynecology). Increased muscle mass at three months is well-documented. Bhasin et al. (2001, NEJM) established dose-dependent muscle hypertrophy in testosterone-treated individuals, and the subjective sense of feeling muscle growth before it's visually obvious is consistent with early neuromuscular adaptations. Facial hair timelines vary widely by genetics, but light upper lip hair at three months is within the reported range.
What did they get wrong (or right)?
The head size change is the one that deserves scrutiny. They said "my head got bigger" and attributed it to testosterone, noting hat fit changed noticeably. There is no strong published evidence that testosterone causes measurable cranial bone growth in adults. Bone remodeling from androgens in adults is documented in jaw structure and brow ridge over years, not months (Zehr et al., 2005, Hormones and Behavior), but skull circumference increasing in three months would be unusual. A more likely explanation: soft tissue changes, scalp thickening, or simply fluctuation in measurement. It is not impossible, but the certainty with which they stated it deserves a raised eyebrow.
The foot-widening claim is similarly plausible but not well-documented in short-term testosterone use. Some individuals report foot changes over longer periods, possibly related to ligament laxity changes or weight redistribution, but three months is a short window. Credit where it is due: they hedged appropriately, saying "I think" and "might have."
The breast tissue response to exercise claim is worth addressing. Testosterone does reduce breast tissue over time in many FTM patients (Nakamura et al., 2019), but the mechanism is primarily fat redistribution, not direct muscle replacement of glandular tissue. Exercise helps reshape the chest but does not remove glandular breast tissue. That requires medical or surgical intervention.
What should you actually know?
If you are researching FTM testosterone therapy, this video is a reasonable anecdotal account, but a few things need clinical context that a three-minute update cannot provide.
- Individual variation in testosterone response is significant. Genetics, baseline hormone levels, the specific formulation and dose used, and body composition all affect timelines and intensity of changes. What happened at month three for this person may not be your month three.
- Menstrual suppression is not the same as contraception. Testosterone is not a reliable contraceptive (Krempasky et al., 2020, Contraception). This video does not address that, but anyone reading about period cessation on T should know the distinction.
- The breast tissue point matters clinically. Exercise reshapes; it does not remove glandular tissue. If chest dysphoria is a concern, that conversation belongs with a physician, not a workout plan alone.
- Testosterone therapy carries real monitoring requirements: hematocrit, lipid panels, liver enzymes, and bone density over time. None of that is this video's job to cover, but if you are starting T without a prescribing clinician tracking labs, that is a problem regardless of how smooth someone else's first three months looked.
Bottom line
This is a good-faith personal account and most of what they described is consistent with the literature. The head size claim is the shakiest. The breast tissue and exercise framing oversimplifies the mechanism. Overall, this is more reliable than most TikTok health content, but it is not a substitute for individualized clinical guidance.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Three-month testosterone updates: separating real changes from hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Three-month testosterone updates: separating real changes from hype is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is approximately three months into masculinizing testosterone therapy and describes a symptom and change profile consistent with early androgenization: clitoral growth, menstrual suppression, early facial and body hair, and increased muscle mass.
FormBlends verdict
The creator is approximately three months into masculinizing testosterone therapy and describes a symptom and change profile consistent with early androgenization: clitoral growth, menstrual suppression, early facial and body hair, and increased muscle mass. The timeline they describe aligns with published onset windows from Endocrine Society clinical practice guidelines for gender-affirming hormone therapy (Hembree et al., 2017, JCEM). No information is provided about formulation, dose, or whether labs are being monitored, which are standard components of medically supervised testosterone therapy.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is approximately three months into masculinizing testosterone therapy and describes a symptom and change profile consistent with early androgenization: clitoral growth, menstrual suppression, early facial and body hair, and increased muscle mass. The timeline they describe aligns with published onset windows from Endocrine Society clinical practice guidelines for gender-affirming hormone therapy (Hembree et al., 2017, JCEM). No information is provided about formulation, dose, or whether labs are being monitored, which are standard components of medically supervised testosterone therapy.
- Clitoral growth is one of the earliest documented changes in FTM testosterone therapy, with onset often within the first weeks, consistent with this creator's report (Grimstad et al., 2021, Andrology).
- Menstrual suppression by month two is possible but on the faster end of the two-to-six-month window reported in prospective cohort data (Nakamura et al., 2019, Obstetrics and Gynecology).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Clitoral growth is one of the earliest documented changes in FTM testosterone therapy, with onset often within the first weeks, consistent with this creator's report (Grimstad et al., 2021, Andrology).
- Menstrual suppression by month two is possible but on the faster end of the two-to-six-month window reported in prospective cohort data (Nakamura et al., 2019, Obstetrics and Gynecology).
- The claim that the skull grew larger in three months is not supported by adult bone remodeling research; soft tissue changes are a more plausible explanation for hat fit differences.
- Exercise reshapes the chest by building pectoral muscle and testosterone shifts fat distribution, but neither eliminates glandular breast tissue, which requires clinical intervention.
- Testosterone is not a reliable contraceptive despite causing menstrual suppression. People on T who have a uterus should discuss contraception with their provider (Krempasky et al., 2020, Contraception).
- Individual variation in testosterone response is significant; genetics, formulation, dose, and baseline labs all affect what changes occur and when, meaning one person's three-month timeline is not predictive of another's.
- Medically supervised testosterone therapy includes regular lab monitoring of hematocrit, lipids, and liver enzymes, none of which this video addresses but all of which are standard of care under Endocrine Society guidelines (Hembree et al., 2017, JCEM).
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Aiden’s Acreage 🇨🇦🏳️⚧️ · TikTok creator
2.3K views on this video
3 month T update physical and mental changes. #testosterone #ftmtransgender #ftm #trans #transmen
Sources & references
- [1]Grimstad et al. (2021)
- [2]Nakamura et al., 2019
- [3]Bhasin et al. (2001)
- [4]Zehr et al., 2005
- [5]Krempasky et al., 2020
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Aiden’s Acreage 🇨🇦🏳️⚧️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.